Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Comparative effectiveness review of biolimus-eluting stents versus bare-metal stents and second-generation drug-eluting stents. Lansdale: HAYES, Inc.. Directory Publication. 2016 Authors' conclusions Drug-eluting stents (DES) are a device/drug combination product consisting of a coronary stent coated in an antiproliferative drug. Stents are placed within an obstructed artery during percutaneous coronary intervention (PCI) to reestablish blood flow in patients with coronary artery disease (CAD). Biolimus-eluting stents (BES) are a group of biodegradable polymer or polymer-free DES that elute the sirolimus derivative with the trade name Biolimus. Biolimus is slowly released to block cell proliferation, thus preventing fibrosis that could otherwise lead to blockage.
Relevant Questions: Are BES effective in reducing death, myocardial infarction, repeat revascularizations,
and improving symptoms in patients with CAD? How do BES compare with alternative stent types such as bare-metal stents (BMS), everolimus-eluting stents (EES), and zotarolimus-eluting stents (ZES) in terms of efficacy and potential harms? Are BES safe for treatment of CAD? Have definitive patient selection criteria been established for the use of BES in patients with CAD? Indexing Status Subject indexing assigned by CRD MeSH Coronary Restenosis; Drug-Eluting Stents; Humans; Stents Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32016000975 Date abstract record published 31/08/2016 |